Trial · NCT00842712
Results by group19
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 19 of 19
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Safety run-in Part: Number of Participants With Dose Limiting Toxicities (DLTs) | Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Gem | 0 | participants | ||
| Safety run-in Part: Number of Participants With Dose Limiting Toxicities (DLTs) | Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Vin | 0 | participants | ||
| Safety run-in Part: Number of Participants With Dose Limiting Toxicities (DLTs) | Safety run-in Part: Cil (2000 mg) + Cetuximab + Cis + Gem | 0 | participants | ||
| Safety run-in Part: Number of Participants With Dose Limiting Toxicities (DLTs) | Safety run-in Part: Cil (2000 mg) + Cetuximab + Cis + Vin | 0 | participants | ||
| Randomized Part: Progression Free Survival (PFS) Time - Independent Read | Randomized Part: Cil (Once Weekly) + Cetuximab + Chemotherapy | 6.2 | 95% Confidence Interval 5.6 to 7.4 | months | |
| Randomized Part: Progression Free Survival (PFS) Time - Independent Read | Randomized Part: Cil (Twice Weekly) + Cetuximab + Chemotherapy | 5.6 | 95% Confidence Interval 4.0 to 7.5 | months | |
| Randomized Part: Progression Free Survival (PFS) Time - Independent Read | Randomized Part: Cetuximab + Chemotherapy | 5.0 | 95% Confidence Interval 4.2 to 5.6 | months | |
| Randomized Part: Progression Free Survival (PFS) Time - Investigator Read | Randomized Part: Cil (Once Weekly) + Cetuximab + Chemotherapy | 5.6 | 95% Confidence Interval 5.4 to 6.7 | months | |
| Randomized Part: Progression Free Survival (PFS) Time - Investigator Read | Randomized Part: Cil (Twice Weekly) + Cetuximab + Chemotherapy | 5.6 | 95% Confidence Interval 4.2 to 7.0 | months | |
| Randomized Part: Progression Free Survival (PFS) Time - Investigator Read | Randomized Part: Cetuximab + Chemotherapy | 5.3 | 95% Confidence Interval 4.2 to 5.7 | months | |
| Randomized Part: Overall Survival (OS) Time | Randomized Part: Cil (Once Weekly) + Cetuximab + Chemotherapy | 13.6 | 95% Confidence Interval 9.5 to 18.6 | months | |
| Randomized Part: Overall Survival (OS) Time | Randomized Part: Cil (Twice Weekly) + Cetuximab + Chemotherapy | 13.6 | 95% Confidence Interval 8.7 to 16.7 | months | |
| Randomized Part: Overall Survival (OS) Time | Randomized Part: Cetuximab + Chemotherapy | 9.7 | 95% Confidence Interval 7.9 to 13.4 | months | |
| Randomized Part: Best Overall Response (BOR) Rate | Randomized Part: Cil (Once Weekly) + Cetuximab + Chemotherapy | 37.6 | 95% Confidence Interval 27.4 to 48.8 | percentage of participants | |
| Randomized Part: Best Overall Response (BOR) Rate | Randomized Part: Cil (Twice Weekly) + Cetuximab + Chemotherapy | 27.5 | 95% Confidence Interval 15.9 to 41.7 | percentage of participants | |
| Randomized Part: Best Overall Response (BOR) Rate | Randomized Part: Cetuximab + Chemotherapy | 29.8 | 95% Confidence Interval 20.3 to 40.7 | percentage of participants | |
| Randomized Part: Time to Treatment Failure | Randomized Part: Cil (Once Weekly) + Cetuximab + Chemotherapy | 4.4 | 95% Confidence Interval 3.5 to 5.6 | months | |
| Randomized Part: Time to Treatment Failure | Randomized Part: Cil (Twice Weekly) + Cetuximab + Chemotherapy | 2.8 | 95% Confidence Interval 1.4 to 4.2 | months | |
| Randomized Part: Time to Treatment Failure | Randomized Part: Cetuximab + Chemotherapy | 4.2 | 95% Confidence Interval 2.8 to 5.3 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00842712/results